The Advisory Board Company Reports Fiscal Year 2010 Second Quart...(------- -------- -------- ...),Health

Date:11/2/2009

------- -------- -------- Cost of services (1) 31,041 28,993 61,105 57,547 Member relations and marketing (1) 13,136 13,058 25,693 25,456 General and admin- istrative (1) 8,835 7,214 15,602 14,109 Depreciation and amortization 1,718 1,327 3,621 2,410 Write-off of capitalized software 7,397 - 7,397 - ----- --- ----- --- (Loss) income from operations (3,804) 7,033 1,608 15,320 Other income, net 584 948 1,546 2,152 --- --- ----- ----- (Loss) income before provision for income taxes (3,220) 7,981 3,154 17,472 Provision for income taxes 1,104 (2,578) (1,082) (5,739) ----- ------ ------ ------ Net (loss) income $(2,116) $5,403 -139.2% $2,072 $11,733 -82.3% ======= ====== ====== ======= (Loss) earnings per share Basic $(0.14) $0.32 $0.13 $0.68 Diluted $(0.14) $0.32 -143.8% $0.13 $0.68 -80.9% Weighted average common shares outstanding Basic 15,527 16,922 15,541 17,143 Diluted 15,662 16,989 15,636 17,352 Contract Value (at end of period) $237,602 $230,636 3.0% Percentages of Revenues Cost of services (1) 53.2% 50.3% 53.1% 50.1% Member relations and marketing (1) 22.5% 22.7% 22.3% 22.2% General a
'/>"/>

SOURCE The Advisory Board Company Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Related medicine news :

1. Important new novel 2009 H1N1 flu advisory for cardiopulmonary transplantation
2. The Advisory Board Company Schedules Second Quarter Conference Call for November 2, 2009
3. Bionovo Adds Dr. Debu Tripathy to Their Medical Advisory Board
4. World-first mental health media initiative announces inaugural Advisory Group
5. Tranziger Announces Formation of Global Advisory & Development Team
6. FDA Advisory Committee Recommends Approval of PEGINTRON(R) for the Adjuvant Treatment of Stage III Malignant Melanoma
7. William Fuchs Named to PerfectServe Advisory Board
8. Data Strategy Invited to Become a Member of VMware's Partner Technical Advisory Board (PTAB)
9. Star Scientific Breaks New Ground, Plans FDA Filing for Approval of First Modified Risk Tobacco Product; Nominates Curtis Wright, MD, MPH for FDA Advisory Committee
10. FDA Advisory Committee Unanimously Recommends Approval of XIAFLEX(TM) for Treatment of Dupuytrens Disease
11. Robert Fanning Named to PerfectServe Advisory Board